Wegovy用户在降低糖尿病和心脏病风险方面实现了关键的健康改善。 Wegovy users achieved key health improvements linked to lower risk of diabetes and heart disease.

诺沃·诺迪斯克报告说,其减重药物使用者Wegovy达到了关键的健康基准,包括腰围和BMI的减少、与2型糖尿病和心脏病等肥胖症相关风险降低有关的水平。 Novo Nordisk reports that users of its weight-loss drug Wegovy® met key health benchmarks, including reductions in waist circumference and BMI, levels associated with lower risk of obesity-related conditions such as type 2 diabetes and heart disease. 调查结果突显了该药物在改善肥胖患者的长期健康结果方面的潜力。 The findings highlight the drug’s potential to improve long-term health outcomes for individuals with obesity.